NCT07762729

Brief Summary

This prospective observational birth cohort study aims to characterize the longitudinal development of the gut microbiome during early childhood and to investigate its associations with prenatal, perinatal, and postnatal exposures and child growth and health outcomes. Approximately 1000 pregnant women will be enrolled, and their children will be followed from birth to 36 months of age. Information on parental demographic and lifestyle characteristics, maternal pre-pregnancy and pregnancy-related factors, prenatal examinations, delivery characteristics, infant feeding, medication use, illnesses, and household and environmental factors will be collected through questionnaires and medical records. Child anthropometric measurements and fecal samples will be collected at birth and at 1, 3, 6, 9, 12, 18, 24, and 36 months of age. The fecal microbiome will be characterized using shotgun metagenomic sequencing.Umbilical cord blood will be collected at delivery from all participants, subject to informed consent and hospital procedures. At 36 months of age, residual venous blood remaining after routine health examinations and clinically indicated laboratory testing will be retained for research from all participating children. The study will evaluate the developmental trajectories of the early-life gut microbiome and identify maternal, paternal, perinatal, feeding-related, medication-related, and environmental factors associated with microbiome development and subsequent child growth and health.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
17mo left

Started Nov 2023

Longer than P75 for all trials

Geographic Reach
1 country

5 active sites

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress67%
Nov 2023Dec 2027

Study Start

First participant enrolled

November 16, 2023

Completed
2.7 years until next milestone

First Submitted

Initial submission to the registry

July 28, 2026

Completed
16 days until next milestone

First Posted

Study publicly available on registry

August 13, 2026

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

August 13, 2026

Status Verified

August 1, 2026

Enrollment Period

4.1 years

First QC Date

July 28, 2026

Last Update Submit

August 11, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in relative abundance of gut microbial taxa measured by shotgun metagenomic sequencing

    Gut microbial taxonomic composition will be characterized from stool samples using shotgun metagenomic sequencing and summarized as the relative abundance of microbial taxa.

    At birth and at 1, 3, 6, 9, 12, 18, 24, and 36 months of age

Secondary Outcomes (4)

  • Change in infant body weight measured by standardized follow-up records

    At birth and at 1, 3, 6, 9, 12, 18, 24, and 36 months of age

  • Change in infant body length measured by standardized follow-up records

    At birth and at 1, 3, 6, 9, 12, 18, 24, and 36 months of age

  • Change in infant head circumference measured by standardized follow-up records

    At 1, 3, 6, 9, 12, 18, 24, 30, and 36 months after birth

  • Infant feeding pattern assessed by standardized follow-up questionnaire

    At 1, 3, 6, 9, 12, 18, 24, 30, and 36 months after birth

Eligibility Criteria

Age0 Months - 36 Months
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Pregnant women and their newborns receiving care at maternal and child health hospitals in Yiyang, Jiangshan, Baoji, and Qidong

You may qualify if:

  • Willing to undergo regular follow-up during the study period

You may not qualify if:

  • Difficulty in follow-up participation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Yiyang Maternal and Child Health Hospital

Yiyang, Hunan, 413000, China

Location

Qidong Maternal and Child Health Hospital

Nantong, Jiangsu, 226200, China

Location

Children's Hospital of Fudan University

Shanghai, Shanghai Municipality, 201102, China

Location

Baoji Maternal and Child Health Hospital

Baoji, Shanxi, 721099, China

Location

Jiangshan Maternal and Child Health Hospital

Quzhou, Zhejiang, 324199, China

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
36 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director, Department of Endocrinology

Study Record Dates

First Submitted

July 28, 2026

First Posted

August 13, 2026

Study Start

November 16, 2023

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

August 13, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing
Will not share

Locations